Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981713 | 0.88 | KDM4E (0.36) | KDM4ECA1CA2CA9KMT2A | |
| SCHEMBL195044 | 0.84 | KDM4E (0.53) | KDM4ECA1CA2CA9KMT2A | |
| SCHEMBL25477260 | 0.84 | KDM4E (0.44) | KDM4ECA1CA2CA9KMT2A | |
| SCHEMBL14934286 | 0.83 | CYP19A1 (0.45) | CYP19A1NR1I2P2RX7 | |
| SCHEMBL179467 | 0.82 | CA2 (0.50) | CA1CA2CA9KMT2ATSHR | |
| SCHEMBL29436012 | 0.82 | CA2 (0.50) | CA1CA2CA9KMT2ATSHR | |
| SCHEMBL2669936 | 0.81 | L3MBTL1 (0.45) | KDM4EKMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL14560151 | 0.80 | ACHE (0.41) | TSHRALDH1A1SMN1; SMN2TDP1CYP19A1 | |
| SCHEMBL19504377 | 0.80 | CNR2 (0.38) | KDM4EKMT2AALDH1A1HSD17B10CYP19A1 | |
| SCHEMBL14560150 | 0.80 | TUBB1 (0.40) | ALDH1A1SMN1; SMN2CYP19A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865809-A | Preparation method of musk with sunflower seeds | 山东兴文工业技术研究院有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | EXSCIENTIA LTD. (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | EXSCIENTIA LTD. (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20230288824-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-11530205-B2 | GLP-1 receptor modulators | RECEPTOS LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210371409-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2021-12-02 | — | — | US | disclosed |
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7605174-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371409-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GCGR | KDM4E 2596/4885CA1 4382/4885CA2 2828/4885 |
| US-11786528-B2 | Pyrazolopyrimidine compounds as adenosine receptor antagonists | ADORA1, ADORA3, ADORA2A | KDM4E 915/4885CA1 3334/4885CA2 897/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | KDM4E 916/4885CA1 3596/4885CA2 3036/4885 |
| US-11530205-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | KDM4E 2429/4885CA1 4143/4885CA2 2538/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | KDM4E 2958/4885CA1 1084/4885CA2 192/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | KDM4E 2346/4885CA1 3713/4885CA2 3077/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | KDM4E 1531/4885CA1 4061/4885CA2 4593/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KDM4E 4340/4885CA1 3378/4885CA2 2487/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | KDM4E 2206/4885CA1 3161/4885CA2 1773/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | KDM4E 2484/4885CA1 4832/4885CA2 3530/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | KDM4E 2049/4885CA1 4704/4885CA2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.